Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Similar Items

• Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
  od: Fiorelli, Alfonso, i dr.
  Izdano: (2020)
• Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
  od: Shepherd, Annemarie F., i dr.
  Izdano: (2020)
• HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
  od: Yamaoka, Toshimitsu, i dr.
  Izdano: (2020)
• Postoperative management for non-small cell lung cancer harboring EGFR mutations
  od: Tanaka, Fumihiro, i dr.
  Izdano: (2020)
• Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
  od: Watanabe, Satomi, i dr.
  Izdano: (2016)